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INTRODUCTION 
 
The  incidence  and  prevalence  of  Type  2  diabetes 
increases with age [1, 2]. It now affects approximately 
18-30% of the elderly population in the United States 
[3,  4].  The  underlying  mechanism(s)  behind  why 
diabetes is increasing in the elderly is still not clearly 
understood.    It  has  been  hypothesized  that  insulin 
resistance increases with age due to increased adiposity, 
decreased lean muscle mass, changes in dietary habits, 
and reduced physical activity [5].  However, it has been 
shown that these factors alone do not account for age-
related  glucose  intolerance  [1].  Many  human  studies, 
some  of  which  are  summarized  below,  have  tried  to 
clarify  the  mechanism  by  which  age-related  glucose 
tolerance develops but have had contradictory results. 
 
Early  studies  on  the  increase  in  peripheral  insulin 
resistance  due  to  age  alone  yielded  inconclusive 
results[6].  For example, in one study comparing young 
(ages  18-36)  and  older  (ages  57-82)  men,  subjects 
underwent frequent measurement of plasma glucose and 
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insulin levels during an intravenous glucose tolerance 
test  with  arginine  potentiation  [7].    This  study  found 
that  there  was  a  significant  decrease  in  the  glucose 
clearance  rate  in  the  older  subjects  despite  elevated 
plasma insulin levels in this population compared to the 
younger men.  These data imply that insulin sensitivity 
decreases  with  age.  In  contrast,  a  different  study  of 
young (ages 19-36) and older (ages 47-73) men used a 
hyperinsulinemic  clamp  model  to  measure  plasma 
glucose  clearance.  In  this  study,  plasma  glucose 
clearance was found to be dependent on the waist-to-hip 
ratio  and  not  age:  higher  waist-to-hip  ratios  were 
associated  with  impaired  plasma  glucose  clearance, 
implying that it is fat distribution that portends insulin 
resistance rather than age alone [8]. 
 
Studies on the age-related effects on the beta cell have 
also  yielded  inconsistent  results.  A  retrospective 
analysis of the European Group for the Study of Insulin  
Resistance  database  revealed  a  25%  decline  in  the 
insulin  delivery  rate  (calculated  as  the  sum  of  the 
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Abstract: The incidence of and susceptibility to Type 2 diabetes increases with age,  but the underlying mechanism(s) 
within beta cells that contribute to this increased susceptibility have not been fully elucidated. Here we review how aging 
affects the proliferative and regenerative capacity of beta cells and how this impacts beta cell mass.  In addition we review 
changes that occur in beta cell function with age. Although we focus on the different rodent models that have provided 
insight into the characteristics of the aging beta cell, the limited knowledge from non-rodent models is also reviewed. 
Further studies are needed in order to identify potential beta cell targets for preventing or slowing the progression of 
diabetes that occurs with age. 
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fasting plasma insulin concentration) from age 18 to 85 
[1].  This study controlled for body mass index (BMI), 
fasting plasma glucose, and insulin sensitivity in both 
men and women.  These results suggested that beta cell 
function declines with age.  In contrast, in a study of 
young (ages 23-25) and older (ages 64-66) adults using 
a hyperglycemic clamp technique, defects in beta cell 
function in older individuals were only observed with 
pre-existing impaired glucose tolerance (IGT) or Type 2 
diabetes; normoglycemic older individuals had a similar 
insulin  response  to  hyperglycemia  as  their  younger 
counterparts [9]. The results of this study suggest that 
there is not necessarily an overall age-related decrease 
in beta cell function but may be observed only in the 
setting of IGT or frank diabetes. 
 
These  macroscopic  studies  are  difficult  to  interpret 
because  glucose  intolerance  can  develop  from  a 
combination of many factors and controlling for every 
possible influence is impossible. Therefore, studies have 
now  focused  on  the  effect  of  aging  on  the  beta  cell, 
specifically on insulin secretion, beta cell mass, and the 
proliferative and regenerative capacity of the beta cell. 
This  review  will  examine  early  theories  on  how  beta 
cell function decline with age as well as explore what is 
known about beta cell proliferation, apoptosis, and the 
role of regeneration and neogenesis in the aging beta 
cell. Finally, the factors that maintain beta cell function 
will be reviewed in relation to age. It is important to 
note that there is currently limited  information in the 
field  on  aging  in  the  non-diabetic  human  and  rodent 
models,  but  what  is  known  will  be  reviewed  here 
(Figure 1). Changes in body mass and insulin resistance 
and the effect that these have on peripheral tissues, such 
as muscle and adipocytes is another topic in itself and 
will not be a subject of this review. 
 
Early  theories  on  why  beta  cell  function  declines 
with age 
 
Early hypotheses on possible causes for the decline in 
beta  cell  function  with  age  considered  theories 
surrounding alterations in glucose oxidation as well as 
alterations  in  potassium  efflux  and  levels  of  calcium 
ions.  In the beta cell, glucose oxidation results in the 
increased ATP production required for insulin secretion.  
Therefore, a reduction in glucose oxidation rates with 
aging would result in reduced insulin secretion. Indeed, 
some  studies  have  shown  that  older  animals  have 
reduced  rates  of  glucose  oxidation  [10].    However, 
subsequent  studies  revealed  that  older  rats  actually 
show an increased rate of both glucose oxidation and 
insulin  secretion,  suggesting  that  this  is  a  potential 
mechanism  by  which  beta  cells  attempt  to  overcome 
age-associated peripheral insulin resistance [10].  
 
There  has  been  some  discussion  that  age  affects  the 
potassium  and  calcium  channels  involved  in  insulin 
secretion.  Normally,  elevated  glucose  concentrations 
induce beta cells to inhibit potassium efflux, resulting in 
increased  calcium  influx  through  voltage-dependent 
calcium channels. The increase in intracellular calcium 
induces  insulin  exocytosis.  In  a  study  of  potassium 
channels comparing 3 month to 24 month old rats, a 
significant  potassium  efflux  even  after  high  glucose 
stimulation was observed in older rats, indicating that 
the normal inhibition of the KATP-channel is lost with 
age [11]. These data indicate that age-related alterations 
in beta cell function could be due to changes in glucose 
oxidation and ion channel function. 
 
 
 
 
 
 
 
 
 
Beta cell proliferation declines with age 
 
The  regenerative  capacity  of  most  organs  decreases 
with  age.    Older  rats  exhibit  reduced  proliferative 
capacity in the form of reduced muscle and bone mass, 
defective  tissue  repair,  and  thinning  of  skin  [12].  
Specifically, this may be due to an age-related reduction 
in  expression  of  the  Forkhead  Box  M1  (FoxM1) 
transcription  factor  [12].    FoxM1  regulates  genes 
involved in cell cycle regulation and cell division.  It is 
highly expressed in proliferating cells, and expression 
declines  in  most  cell  types  with  age,  including 
pancreatic islets [13]. Genetic inactivation of the Foxm1 
gene  throughout  the  pancreatic  epithelium  results  in 
reduced postnatal beta cell proliferation [13-15]. 
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Figure 1: Summary of the effects of age on various beta cell 
parameters. Multiple factors influence the beta cell as it ages.  
Each of the factors listed here is discussed in more detail in the 
text.  This graph is a representation of how these parameters 
change with age.  The actual kinetics of each of these changes 
has not been fully elucidated. Beta cell proliferation is also reduced in humans with 
age [16, 17]. A small study of pancreata from twenty 
non-diabetic  organ  donors  aged  7  to  66  showed  a 
decline  in  beta  cell  replication  with  age  [16].  The 
decline in beta cell replication was directly associated 
with  a  decrease  in  expression  of  the  pancreatic  and 
duodenal  homeobox  1  (pdx1)  [16],  a  transcription 
factor, known to be important for beta cell replication 
[18] and will be discussed further later in this paper. In 
another study, a review of 124 pancreata from obese, 
diabetic,  and  lean  individuals  aged  61-83  at  autopsy, 
showed  that  in  this  population,  there  was  also  a  low 
frequency of beta cell replication [17]. 
 
Cell  cycle  activators  and inhibitors  are  targets for 
promoting beta cell replication. 
 
Investigating  the  expression  and  function  of  different 
cell cycle activators and inhibitors in the beta cell could 
elucidate mechanisms by which beta cell replication can 
be  promoted  to  enhance  beta  cell  mass  (and 
subsequently  possibly  function),  especially  in  the 
setting  of  diabetes.    Beta  cells  express  most  of  the 
known  cell  cycle  inhibitors,  including  p16
INK4a, 
p18
INK4c, p21
CIP1, p27
Kip1, p53, and Rb [19].  In contrast,  
there is much less redundancy of cell cycle activators in 
the beta call.  For example, rodent beta cells express 
only Cdk4 (cyclin-dependent kinase 4) and not Cdk6, 
whereas  most  other  cell  types  express  both  of  these 
closely related proteins [20]. 
 
Mouse beta cells express all three D cyclins, D1, D2, 
D3,  but  the  mRNA  expression  of  D2  is  significantly 
higher than both D1 and D3 with only D2 detectable by 
immunohistochemistry [21]. The D cyclins promote the 
passage  of  cells  past  the  G  phase  checkpoint  and  in 
conjunction  with  the  cyclin-dependent  kinases  [22]. 
Loss of a single cell cycle inhibitor does not accelerate 
beta cell cell cycle progression, whereas loss of multiple 
inhibitors enhances beta cell proliferation [23] [24] [25].  
For  example,  beta  cell-specific  inactivation  of  the Rb 
gene has minimal effect on beta cell replication rates, 
pancreatic  insulin  content,  and  beta  cell  mass  [26].  
Conversely, loss of a single cell cycle activator leads to 
profound defects in beta cell replication and beta cell 
mass. Specifically, loss of Cdk4 leads to a reduction in 
mRNA  levels  of  insulin  I,  insulin  II,  islet  amyloid 
polypeptide, and Glut2 as well as decreased beta cell 
area  (from  deformed  and  smaller-size  islets)  [27]. 
Additionally, loss of the transcription factor FoxM1 in 
the pancreatic epithelium results in decreased postnatal 
beta  cell  mass  [13],  at  least  in  part  due  to  increased 
nuclear p21 levels and decreased Cdk2 activation  via 
reduced  Cdc25A  phosphatase  expression  [28].  This 
phenomenon  points  to  the  potentially  greater 
importance  of  regulating  cell  cycle  “brakes”  or 
inhibitors  rather  than  solely  trying  to  increase 
expression of a particular “accelerator” or activator.  
 
Cell cycle activators: As mentioned above, D cyclins 
and cyclin-dependent kinases promote progression from 
G phase to S phase. Loss of cyclin D1 and D2 in beta 
cells has no effect on islet size or number, indicating 
that  these  cell  cycle  activators  are  not  important  to 
embryonic beta cell development. However, cyclin D2 
null  mutant  mice  develop  diabetes  by  9-12  months, 
which  suggests  that  it  is  critical  to  adult  beta  cell 
expansion  [21].  Studies  by  He  et  al.  indicate  that 
phosphorylation of threonine 280 (T280) within cyclin 
D2  limit  its  stability.  Transgenic  mice  expressing  a 
mutant form of cyclin D2 under the insulin promoter, 
where  T280  was  mutated  to  alanine  allowing  for 
increased  levels  of  D2  expression,  showed  increased 
beta cell mass at 18-21 months [30]. Transgenic mice 
over-expressing cyclin D1 displayed increased beta cell 
proliferation,  interestingly  without  inducing  tumor 
formation [29]. Cyclin D3 levels are nearly undetectable 
in mouse islets and no studies have been performed to 
examine the impact of an absence of cyclin D3 in the 
beta cell. In contrast, cyclin D3 is highly expressed in 
the human beta cell, with only minimal cyclin D1 and 
D2  levels  noted.  Interestingly,  cyclin  D3  over-
expression  (in  isolated  human  islets),  especially  in 
combination with cdk6, induced the greatest increase in 
beta  cell  proliferation  when  compared  with  over-
expression of other cyclins (cyclins D1,2,3 and cdk 4 
and 6) [31]. 
 
Through  their  interaction  with  the  cyclins,  Cdk’s 
inactivate cell cycle inhibitors allowing for cell cycle 
progression  [32].  Cdk4  null  mutant  mice  show  no 
impairment  in  embryonic  beta  cell  development,  but 
postnatally they have a significant reduction in beta cell 
mass compared to controls. In fact, by age 17 weeks, 
beta cell mass of Cdk4 null mutant mice is only 10% of 
that of age-matched controls. Null mutants have a 3.5-
fold  reduction  in  BrdU  incorporation  as  well,  but, 
interestingly, only beta cells, and not other pancreatic 
endocrine  cell  types,  are  affected  [20].  Additionally, 
mice  were  generated  with  a  mutation  in  the  Cdk4 
protein such that it could no longer be down-regulated 
by  p16
INK4a.  In  this  model,  there  was  a  7-10  fold 
increase in islet cell area with no significant change in 
glucose  tolerance  when  compared  to  wild-type 
littermate controls aged ≥ 3 months [27]. Cdk2 is also 
present in the mouse islet [33], but its specific role in 
beta  cells  has  not  yet  been  elucidated.  Cdk6,  though 
important  to  the  cell  cycle  in  other  cell  types,  is  not 
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driving beta cell replication in human islets [31]. The 
effect of age on cyclin D and Cdk levels has not yet 
been examined.  
 
Cell cycle inhibitors:  Evidence from multiple labs has 
demonstrated that with age, beta cells show decreased 
expression  of  cell  cycle  activators  (e.g.,  FoxM1 
mentioned  above)  with  simultaneous  increases  in 
expression  of cell  cycle  inhibitors.    For  example,  the 
p16
Ink4a tumor suppressor protein (expressed from the 
INK4a/ARF  (Cdkn2a)  locus),  which  sequesters  Cdk4 
and  Cdk6  and  prevents  their  interaction  with  the  D 
cyclins, increases with age in both rodent and human 
islets [34].  In the absence of p16
Ink4a, Cdk4 and Cdk6 
complex  with  Cyclin  D  and  phosphorylate  pRB, 
releasing the E2F transcription factor, which facilitates 
the G to S phase cell cycle transition.  Increased p16
Ink4a 
is  associated  with  cell  cycle  arrest  and  cellular 
senescence  (see  Figure  2)  [32].    Beta  cell-specific 
transgenic  over-expression  of  p16  decreases  beta  cell 
proliferative capacity  in  young mice (26-32 weeks of 
age) to levels observed in older mice [34].  Conversely, 
germline  deletion  of  p16
Ink4a  significantly  ameliorates 
age-related decreases in beta cell proliferative capacity.  
In the absence of p16
Ink4a, beta cells from mice at ~60 
weeks of age showed levels of proliferation comparable 
to  beta  cells  from  younger  mice  (10  weeks  of  age).  
Proliferation  still  declined  with  age  in  mice  lacking 
INK4a, but this was thought to be related to either the 
effect  of  p19
Arf  expression  or  a  mechanism  that  was 
independent of the products of the Ink4a/Arf locus [34]. 
p19
Arf (known as p14
ARF in humans) is the other product 
of  the  INK4a/Arf  gene  locus.    This  protein  is  also 
involved  in  cell  cycle  progression  but  by  a  different 
mechanism (see Figure 3).  The function of this protein 
has been examined in the cancer and stem cell fields but 
little  is  known  about  its  role  in  pancreatic  islets.  
Interestingly,  in  other  cell  types,  p19
Arf  has  been 
implicated as a direct inhibitor of FoxM1 [35]. 
 
The  decline  in  beta  cell  proliferation  with  age  may 
result  in  part  from  decreased  expression  of  specific 
growth  factor/hormone  receptors  or  their  downstream 
signaling components. For example, treatment with the 
glucagon-like  peptide-1  (GLP-1)  analog,  Exendin-4 
increases beta cell mass in young mice (6 weeks old) 
but  not  in  mice  aged  7-8  months,  indicating  that  the 
aged  beta  cell  does  not  respond  very  well  to  GLP-1 
[36]. Exendin-4 treatment results in a marked decrease 
in p16
Ink4a levels in young but not old mice, reinforcing 
the  concept  that  p16
Ink4a  contributes  to  the  reduced 
proliferative capacity of the older beta cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p16
Ink4a  also  plays  a  role  in  beta  cell  regeneration.  
Streptozotocin  (STZ)  causes  beta  cell  necrosis  and 
diabetes after a single, high dose injection in adult mice, 
and  beta  cell  regeneration  following  destruction  has 
been  well-established  [37].    p16
Ink4a  +/+,  +/-,  and  -/- 
mice  were  injected  with  STZ,  resulting  in  beta  cell 
necrosis and diabetes in all genotypes. However, by 9-
15  weeks  of  age  p16
Ink4a  +/+
  and  +/-  mice  showed 
persistent hyperglycemia compared to their p16
Ink4a -/- 
littermates, although even the p16
Ink4a deficient mice did 
not  show  complete  recovery  to  pre-STZ  levels  of 
glucose tolerance, survival, and weight. These data once 
again highlight p16
Ink4a-independent regulation of beta 
cell regenerative capacity with age [34]. 
 
Figure 2: Effects of p16
Ink4a on Cdk4/6. (A) The p16
Ink4a cell cycle 
inhibitor sequesters Cdk4 or Cdk6, preventing interactions with 
cyclin  D  proteins,  and  thus  phosphorylation  of  pRB.  
Hypophosphorylated  pRB  sequesters  the  E2F  transcription 
factor,  thus  thus  inihibiting  cell  cycle  progression.  (B)  In  the 
absence of p16
Ink4a, cyclin D forms a productive complex with 
either  Cdk4  or  Cdk6  and  phosphorylates  RB.  This 
phosphorylation releases the E2F transcription factor, facilitating 
the G1 to S phase cell cycle transition. Thus, in the presence of 
elevated p16
Ink4a, such as with aging, there is cell cycle arrest 
and cellular senescence.  Adapted from [32] 
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Inhibiting  the  inhibitors:  Because  inhibitors  like 
p16
Ink4a reduce the proliferative capacity of the beta cell, 
inhibiting cell cycle inhibitors could offer an alternative 
way to circumvent this deficit.  B-cell-specific Moloney 
murine  leukemia  virus  integration  site  1(Bmi-1)  and 
Enhancer  of  zeste  homologue  2  (Ezh2)  are 
transcriptional regulators in the Polycomb family.  Bmi-
1 is part of the multiprotein histone E3 ubiquitin ligase 
complex,  polycomb  repressor  complex  1  (PRC1;  see 
Figure  4)  and  is  important  for  maintaining  the 
enzymatic  activity  of  the  complex  as  well  as  its 
structure  [38],  while  Ezh2  is  a  component  of  PRC2 
involved  in  methylation  of  lysine  27  of  histone  H3 
(H3K27) and recruitment of PRC1.  These complexes 
are  both  involved  in  transcriptional  repression  of  cell 
cycle  inhibitors  including  p16
Ink4a  and  p19
Arf,  in  the 
pancreas and other tissues. 
 
Within  the  postnatal  pancreas,  Bmi-1  is  localized  to 
islets and its expression decreases significantly from 2 
to 10 weeks of age [38]. Ezh2 is expressed in the beta 
cells of the pancreas, and its expression also decreases 
with age [39]. Using mice lacking Bmi-1, Dhawan et al. 
showed a significant increase in p16
Ink4a mRNA as well 
as  severely  reduced  Ki67  reactivity,  a  marker  of 
proliferation, when comparing 2 week old mice to 10 
week  old  mice  [38].  These  data  show  that  Bmi-1  is 
critical  to  suppression  of  p16
Ink4a  and  that  beta  cell 
proliferation  is  greatly  reduced  in  the  absence  of  its 
silencing.  Mice  with  conditional  gene  inactivation  of 
Ezh2 in the beta cell showed a premature increase in 
p16
Ink4a and p19
Arf mRNA expression and reduced  beta 
cell proliferation and mass, hypoinsulinemia, and mild 
diabetes in one month old mice. Interestingly, there was 
no  change  in  mRNA  levels  of  other  Ink4  or  cdk 
inhibitors (Ink4b, Ink4c, Ink4d, p21
Cip1, p27
Kip1, Trp 53) 
suggesting  that  Ezh2  has  a  specific  effect  on  the 
INK4a/Arf locus in the beta cell [39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The role of apoptosis in decreased beta cell mass  
 
In a study of human pancreatic tissue by Reers et al., the 
decline in beta cell replication with age was not found 
to  be  associated  with  a  change  in  the  frequency  of 
apoptosis [16]. In contrast, a study by Butler showed 
both  a  low  frequency  of  beta  cell  replication  and  a 
higher rate of beta cell apoptosis in obese and diabetic 
individuals  compared  with  lean  and  non-diabetic 
individuals  [17].  Specifically,  the  non-diabetic  obese 
Figure 3: Effects of p19
Arf on the cell cycle. In the absence of 
p19
Arf, p53 is ubiquitinized and subsequently degraded by the 
proteosome.  p19
Arf  inhibits  the  ubiquitin-modulated  effect  of 
p53  by  MDM2.  p19
Arf  inhibits  ubiquitin-mediated  p53 
degradation resulting in induction of p21 and subsequently cell 
cycle arrest. Adapted from [75] and [76] 
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Figure 4: BMI-1 and Ezh2: Effects on transcription. (A) The Ezh2 
(Enhancer  of  zeste  homologue  2)  component  of  the  PRC2 
(Polycomb repressor complex 2) complex methylates lysine (K) 
27 of histone H3 (H3K27). This methylation process recruits the 
PRC1 (Polycomb repressor complex 1) complex. (B) The Ring1A 
and Ring1B components of this complex ubiquitylate H2AK119. 
This ubiquitylation causes transcriptional repression, for example 
at the Ink4a/Arf locus. In addition to Ezh2, the PRC2 complex 
contains  EED  (embryonic  ectoderm  development)  and  Suz12 
(suppressor of zeste homologue 12). The PRC1 complex contains 
BMI-1, Ring 1A, Ring 1B, PH1 (Polycomb homologue 1), and PH1 
(Polyhomeotic homologue 1). Adapted from [77]. individuals  had  a  ~50%  increase  in  relative  beta  cell 
volume (ie. beta cell area/exocrine area) compared to 
non-diabetic  lean  controls;  obese  individuals  with 
impaired fasting glucose and Type 2 diabetes had a 40-
63% beta cell volume deficit compared to obese non-
diabetic controls. This indicates that those individuals 
with  dysglycemia  were  unable  to  adaptively  increase 
their beta cell volume. Ki67 (a marker of proliferation) 
labeling of the pancreata showed that all individuals had 
a  low  frequency  of  replication,  although  there  was  a 
trend toward decreased beta cell replication with age. 
When normalized for beta cell mass, there was a three-
fold and ten-fold increase in beta cell apoptosis in obese 
and  lean  diabetic  individuals  compared  to  obese  and 
lean non-diabetic individuals respectively as observed 
by  TUNEL  staining  [17].  This  balance  of  replication 
and  apoptosis  is  important  to  remember  when 
considering  whether  the  decline  in  beta  cells  in  the 
elderly is truly an issue of inadequate proliferation or 
whether there is also elevated apoptosis. These studies 
indicate that in the non-diabetic individuals, even when 
controlling  for  obesity,  which  causes  higher  rates  of 
apoptosis, enhancing beta cell replication alone may be 
inadequate. 
 
Amylin aggregation: Islet amyloid polypeptide (IAPP) 
or  amylin  [40]  is  a  thirty-seven  amino  acid 
neuroendocrine hormone that is co-secreted with insulin 
from  the  beta  cell  [41].  Amylin  suppresses  glucagon 
secretion  and  in  conjunction  with  insulin  helps  to 
regulate glucose homeostasis [42]. In Type 2 diabetics, 
hypersecretion  of  insulin  results  in  increased  co-
secretion  of  amylin.  This  amylin  aggregates  into 
amyloid  plaques,  which  can  subsequently  lead  to 
increased beta cell apoptosis and cause progression of 
diabetes [43]. Amyloid plaques are present in >90% of 
Type 2 diabetics at autopsy [44]. 
 
With age there is an increased deposition of amylin in 
the  islets  of  diabetic  individuals  but  not  non-diabetic 
individuals  as  seen  by  examination  of  pancreata  at 
autopsy  [45].  Interestingly,  rodent  amyloid  does  not 
aggregate due to a proline amino acid substitution that 
makes  the  rodent  IAPP  differ  from  human  IAPP 
(hIAPP) [46]. Therefore, to study the effects of amylin 
aggregation  on  the  beta  cell,  transgenic  mice  were 
developed that expressed human (h)IAPP under control 
of  the  insulin  promoter.  Over-expression  of  hIAPP 
resulted  in  hyperglycemia  in  male  mice  aged  6  to  9 
months  without  the  presence  of  amyloid  plaques.  In 
older (>13 month) transgenic male  mice, there was a 
significant  amount  of  amylin  plaque  formation  in  the 
peripheral and perivascular areas of the islets only [47]. 
Hyperglycemia  preceded  the  formation  of  obvious 
plaques, suggesting that the hyperglycemia could be, at 
least in part, due to cytotoxicity from intermediate-sized 
amyloid  particles.  Janson  et  al.  showed  that  when 
applying  freshly  dissolved  hIAPP  exogenously  to 
dispersed mouse and human islets, islet cell apoptosis 
and necrosis occurred within 24 to 48 hours. In contrast, 
when  islets  were  treated  with  large  amyloid  deposits, 
there was no observable effect. Further study showed 
that  the  intermediate-sized  amyloid  particles  caused 
membrane  damage  and  subsequent  cell  death  [48]. 
From  these  data,  it  is  clear  that  increases  in  amylin 
deposition size can cause increased beta cell death and 
progression of Type 2 diabetes, however the size of the 
particles  may  be  critical  to  determining  whether  they 
have detrimental effects. These results demonstrate that 
increased rates of beta cell apoptosis, in the absence of 
any known defect in proliferation capability, can lead to 
reduced beta cell mass. 
 
Mechanisms  for  increasing  beta  cell  mass, 
regeneration or neogenesis 
 
As  discussed  above,  beta  cell  proliferation  decreases 
with age, but how do beta cells adapt and increase their 
beta  cell  mass?  FoxM1  is  important  to  beta  cell 
replication, and its role in tissue regeneration was first 
appreciated  using  partially  hepatectomized  mice.  
Transgenic  restoration  of  FoxM1  expression  in  older 
hepatocytes to levels similar to those found in young 
mice  resulted  in  improved  liver  regeneration  in  older 
mice  [12].  Genetic  inactivation  of  the  Foxm1  gene 
throughout  the  pancreatic  epithelium  results  in  a 
reduced ability of beta cells to respond to proliferative 
stimuli  and  impaired  beta  cell  regeneration  following 
partial  pancreatectomy  [13-15].  Studies  from  the 
Kushner lab revealed that beta cell mass expansion in 
response  to  multiple  different  stimuli  (partial 
pancreatectomy,  beta  cell  destruction,  and  GLP-1 
analog) severely declines with age [49], possibly due to 
the decrease in Foxm1 expression. 
 
It has become clear in recent years, at least in rodent 
models, that increases in beta cell number postnatally 
occur mainly through proliferation of existing beta cells, 
with little to no contribution from neogenesis from stem 
or  progenitor  cells  [50]  [51].    Taken  together,  these 
studies suggest that the loss of proliferative capacity of 
existing  beta  cells,  rather  than  the  loss  of  progenitor 
cells,  is  likely  cause  of  reduced  beta  cell  mass 
expansion in older individuals. 
 
Pregnancy  is  a  condition  under  which  there  is  an 
increased demand for insulin production and secretion, 
although  the  mechanism  by  which  this  occurs  in 
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insulin response during pregnancy results in gestational 
diabetes. During pregnancy, rodents exhibit both beta 
cell  hyperplasia  and  hypertrophy  [52].  In  contrast,  a 
review  of  44  human  pancreata  from  pregnant,  post-
partum, and non-pregnant women at autopsy suggested 
that the increase in insulin-positive area in pregnant and 
post-partum  women  was  most  likely  due  to  islet 
neogenesis  rather  than  proliferation  [53].  Surrogate 
markers for neogenesis include the number of insulin-
positive cells within or near pancreatic ducts and single 
insulin-positive cells scattered throughout the exocrine 
pancreas.    However,  the  role  of  proliferation  versus 
neogenesis  in  pregnant  human  females  is  still 
controversial  as  studies  from  Van  Assche  et  al. 
concluded that beta cells undergo both hyperplasia and 
hypertrophy during pregnancy [54]. These differences 
may be accounted for by a smaller study population (5 
pregnant and 5 non-pregnant women) in the Van Assche 
study,  differences  in  techniques  used  (Ivic’s  Victoria 
blue  acid  fuchsin  staining  vs.  insulin 
immunohistochemistry to ascertain fractional endocrine 
and beta cell area), and underlying disease conditions 
that may have influenced the beta cell. Thus, in contrast 
to the rodent model, in human pregnancy, an increase in 
beta  cell  number  may  result  from  mechanisms  other 
than  increased  beta  cell  replication,  perhaps  islet 
neogenesis.  It  is  important  to  note  though  that  the 
rodents  used  in  the  pregnancy  studies  were  young 
adults, in contrast to the subjects in published human 
studies.  Younger  individuals  would  be  expected  to 
demonstrate  increased  beta  cell  replication  and 
hypertrophy  during  pregnancy;  epigenetic  changes  in 
beta cells that occur with age likely result in decreased 
response of beta cells to replication cues in both rodents 
and humans with age [55]. 
 
As  previously  mentioned,  beta  cell  loss  may  be 
accompanied by a reduction in islet neogenesis or beta 
cell  proliferation,  and/or  increased  apoptosis.  To 
elucidate  the  rate  of  human  beta  cell  turnover, 
examination  of  ten  human  cadaver  pancreata  was 
undertaken.  These  ten  individuals  had  received 
iododeoxyuridine (IdU) or bromodeoxyuridine (BrdU) 
from  eight  days  to  four  years  prior  to  death  during 
cancer treatment clinical trials. Radiocarbon dating and 
in  vivo  thymidine  analog  staining  showed  that  only 
individuals  under  the  age  of  thirty  years  showed 
evidence  of  beta  cell  turnover.  This  implies  that 
therapies directed at beta cell expansion may not be as 
effective in individuals over the age of thirty [56]. 
 
Since  pregnancy  is  a  physiological  condition  during 
which  there  is  an  appropriate  response  to  increased 
insulin demand, this is an excellent model to investigate 
the mechanisms by which insulin production or beta cell 
mass could be increased in adults. Although there is a 
consistent increase in beta cell mass observed in both 
rodents  and  humans  during  pregnancy,  the 
mechanism(s)  underlying  this  expansion  have  not  yet 
been  fully  elucidated  and  may  differ  significantly  in 
rodent  and  human  pregnancy.  From  a  limited 
examination of human pancreata, it seems that beta cell 
turnover is severely diminished in individuals older than 
thirty and thus, strategies to improve the receptivity of 
older  beta  cells  to  proliferative  cues  should  be 
investigated. 
 
Factors  regulating  beta  cell  function  and 
maintenance of differentiation. 
 
Pdx1  and  MafA:  Pdx1  (pancreatic  and  duodenal 
homeobox 1), also known as IDX1, IPF1, STF1, and 
GSF,  is  a  transcription  factor  critical  for  beta  cell 
development  and  function.  Mice  with  late  onset  beta 
cell-specific Pdx1 inactivation displayed approximately 
60% of the normal number of beta cells and 10% of 
total pancreatic insulin content compared to wild type 
mice at three weeks of age.  Additionally, these mice 
had an increased number of glucagon-expressing cells 
as compared to wild type, with 22% of the glucagon- or 
insulin-expressing  cells  co-expressing  both  hormones 
[57].  Homozygous  pdx1  inactivation  during 
embryogenesis  results  in  early  onset  diabetes  due  to 
decreased beta cell mass and increased alpha cell area at 
birth [18] while a heterozygous inactivation results in 
persistent hyperglycemia with a relative deficiency of 
plasma insulin. Although beta cell mass was unchanged, 
non-beta cell islet mass was nearly doubled suggesting 
that  the  heterozygous  inactivation  of  Pdx1  leads  to 
impairments  in  glucose  homeostasis  [58].  Supporting 
this  conclusion,  islets  from  pdx1  heterozygous  mice 
released approximately 45% less insulin in response to a 
glucose  stimulus  compared  to  wild-type  islets  [59]. 
These data show the importance of Pdx1 in maintaining 
the  beta  cell  phenotype  in  the  adult  mouse  and 
repressing glucagon expression in insulin-positive cells. 
 
Seven to eight month old rats show a decreased number 
of  insulin-positive  cells  that  express  Pdx1  [60],  and 
56% and 33% reduction in pdx1 mRNA levels in 22 
month  old  compared  to  2  month  old  rats  and  mice 
respectively [61]. Acute deletion of Pdx1 at 3 months 
results in an acute reduction of Pdx1 but does not cause 
any  changes  in  glucose  homeostasis.  A  doxycycline-
inducible transgenic system in which expression of an 
antisense ribozyme that cleaves the pdx1 mRNA at a 
specific site, leading to a reduced Pdx1 protein level, 
   
www.impactaging.com                 571                                              AGING, June 2011, Vol.3 No.6 was  utilized  to  examine  the  effect  of  reduced  Pdx1 
function in older vs. younger mice. After 3 weeks of 
doxycycline  treatment,  18  month  old  transgenic  mice 
had  significantly  worse  glucose  tolerance  than  age-
matched  controls  [62].  It  can  thus  be  concluded  that 
Pdx1 expression declines with age in mouse beta cells, 
that this contributes to reduced beta cell function, and 
that beta cell function is particularly affected by reduced 
pdx1 levels with age. 
 
MafA is a beta cell-restricted transcription factor, which 
in  combination  with  transcription  factors  Pdx1  and 
Beta2  synergistically  activates  the  insulin  promoter 
[63]. The effect of age on MafA expression levels has 
not yet been studied, but it has been shown that MafA 
null  mutant  mice,  though  normoglycemic  at  birth, 
develop  diabetes  by  four  weeks  of  age  [64].  This 
suggests  that  MafA  may  be  important  to  maintaining 
glucose  homeostasis  as  animals  age.  It  is  therefore 
possible that with age individuals who develop diabetes 
could  have  some  disruption  in  MafA  levels  as  it  is 
already known that in diabetes, MafA levels are reduced 
[65, 66]. Glucose toxicity causes reduced insulin gene 
expression [67], perhaps due to reduced MafA and Pdx1 
levels, the loss of MafA precedes the reduction of Pdx1 
[68]. Restoring MafA and Pdx1 levels to pre-glucotoxic 
levels virtually completely rescues insulin mRNA levels 
[69]. 
 
Antioxidants: Oxidative stress increases with age [70] 
in many tissues, and this is probably also true in the beta 
cell. Glucose toxicity increases intraislet peroxide levels 
[71] and treatment with antioxidants improves glucose 
levels by reducing apoptosis rates [72] and improving 
insulin  gene  expression,  insulin  secretion,  and  Pdx1 
binding to the insulin promoter [73]. In the db/db obese 
mouse model, it has been shown that reversing beta cell 
oxidative  stress  by  glutathione  peroxidase  over-
expression, restored MafA expression and subsequently 
improved  beta  cell  volume  and  glucose  homeostasis 
[74].  
 
CONCLUSION 
 
An  increased  incidence  of  diabetes  is  observed  with 
age, and there are many possibly reasons for this. One 
of these is that the beta cell has reduced proliferative 
capacity  and  in  diabetic  individuals  this  is  further 
confounded by higher rates of beta cell apoptosis. The 
currently  known  underlying  mechanisms  behind  the 
reduction  in  beta  cell  proliferation  observed  with  age 
include  reduced  expression  of  cell  cycle  activators, 
increased  expression  of  cell  cycle  inhibitors,  reduced 
pdx1  expression,  and  increased  amylin  aggregation. 
Studying aging in the non-diabetic rodent and human 
models is currently a developing field; therefore very 
few broad conclusions can be drawn. Further study in 
these areas is important as they could indicate targets 
for  preventing  or  slowing  the  progression of  diabetes 
with age. 
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